Andrew Berens
Stock Analyst at Leerink Partners
(1.38)
# 3,376
Out of 4,876 analysts
125
Total ratings
47%
Success rate
-9.86%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Andrew Berens
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ARVN Arvinas | Downgrades: Market Perform | $10 → $9 | $7.57 | +18.97% | 6 | Jun 2, 2025 | |
| CMPX Compass Therapeutics | Upgrades: Outperform | $4 → $6 | $2.55 | +135.29% | 3 | Apr 2, 2025 | |
| AGIO Agios Pharmaceuticals | Downgrades: Market Perform | $60 → $56 | $33.45 | +67.41% | 11 | Sep 27, 2024 | |
| CELC Celcuity | Initiates: Outperform | $29 | $12.57 | +130.71% | 1 | Jul 22, 2024 | |
| BPMC Blueprint Medicines | Upgrades: Market Perform | $50 → $97 | $128.10 | -24.28% | 24 | May 6, 2024 | |
| COGT Cogent Biosciences | Maintains: Outperform | $18 → $20 | $7.15 | +179.72% | 4 | Jan 5, 2023 | |
| AZN AstraZeneca | Maintains: Outperform | $78 → $79 | $69.80 | +13.18% | 12 | Nov 14, 2022 | |
| CGEM Cullinan Therapeutics | Maintains: Outperform | $36 → $25 | $7.70 | +224.68% | 3 | May 13, 2022 | |
| AURA Aura Biosciences | Initiates: Outperform | $40 | $6.25 | +540.00% | 1 | Nov 23, 2021 | |
| CCCC C4 Therapeutics | Initiates: Outperform | $67 | $1.44 | +4,552.78% | 1 | Oct 14, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $125 → $140 | $79.94 | +75.13% | 2 | Jun 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $9 → $1 | $0.37 | +170.27% | 5 | Mar 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $33 | $2.39 | +1,280.75% | 1 | Dec 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $10 → $25 | $12.41 | +101.53% | 10 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $74 → $96 | $110.53 | -13.15% | 1 | Oct 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $78 | $68.08 | +14.57% | 12 | Dec 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $35 → $48 | $52.73 | -8.97% | 5 | Apr 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $37 → $28 | $11.67 | +139.93% | 3 | Dec 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $42 → $27 | $1.19 | +2,168.91% | 7 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $40 → $30 | $1.24 | +2,319.35% | 4 | Aug 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | $20 | $4.56 | +338.60% | 1 | Oct 14, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $25 | $4.99 | +401.00% | 1 | Sep 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $16 → $8 | $9.20 | -13.04% | 7 | Jul 14, 2017 |
Arvinas
Jun 2, 2025
Downgrades: Market Perform
Price Target: $10 → $9
Current: $7.57
Upside: +18.97%
Compass Therapeutics
Apr 2, 2025
Upgrades: Outperform
Price Target: $4 → $6
Current: $2.55
Upside: +135.29%
Agios Pharmaceuticals
Sep 27, 2024
Downgrades: Market Perform
Price Target: $60 → $56
Current: $33.45
Upside: +67.41%
Celcuity
Jul 22, 2024
Initiates: Outperform
Price Target: $29
Current: $12.57
Upside: +130.71%
Blueprint Medicines
May 6, 2024
Upgrades: Market Perform
Price Target: $50 → $97
Current: $128.10
Upside: -24.28%
Cogent Biosciences
Jan 5, 2023
Maintains: Outperform
Price Target: $18 → $20
Current: $7.15
Upside: +179.72%
AstraZeneca
Nov 14, 2022
Maintains: Outperform
Price Target: $78 → $79
Current: $69.80
Upside: +13.18%
Cullinan Therapeutics
May 13, 2022
Maintains: Outperform
Price Target: $36 → $25
Current: $7.70
Upside: +224.68%
Aura Biosciences
Nov 23, 2021
Initiates: Outperform
Price Target: $40
Current: $6.25
Upside: +540.00%
C4 Therapeutics
Oct 14, 2021
Initiates: Outperform
Price Target: $67
Current: $1.44
Upside: +4,552.78%
Jun 24, 2025
Maintains: Outperform
Price Target: $125 → $140
Current: $79.94
Upside: +75.13%
Mar 21, 2025
Downgrades: Market Perform
Price Target: $9 → $1
Current: $0.37
Upside: +170.27%
Dec 5, 2024
Initiates: Outperform
Price Target: $33
Current: $2.39
Upside: +1,280.75%
Nov 7, 2024
Upgrades: Outperform
Price Target: $10 → $25
Current: $12.41
Upside: +101.53%
Oct 21, 2024
Upgrades: Outperform
Price Target: $74 → $96
Current: $110.53
Upside: -13.15%
Dec 13, 2023
Upgrades: Outperform
Price Target: $78
Current: $68.08
Upside: +14.57%
Apr 17, 2023
Maintains: Outperform
Price Target: $35 → $48
Current: $52.73
Upside: -8.97%
Dec 13, 2022
Maintains: Outperform
Price Target: $37 → $28
Current: $11.67
Upside: +139.93%
Nov 10, 2022
Maintains: Outperform
Price Target: $42 → $27
Current: $1.19
Upside: +2,168.91%
Aug 11, 2022
Maintains: Outperform
Price Target: $40 → $30
Current: $1.24
Upside: +2,319.35%
Oct 14, 2021
Initiates: Market Perform
Price Target: $20
Current: $4.56
Upside: +338.60%
Sep 20, 2021
Initiates: Outperform
Price Target: $25
Current: $4.99
Upside: +401.00%
Jul 14, 2017
Maintains: Equal-Weight
Price Target: $16 → $8
Current: $9.20
Upside: -13.04%